JPWO2020023794A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020023794A5
JPWO2020023794A5 JP2021527017A JP2021527017A JPWO2020023794A5 JP WO2020023794 A5 JPWO2020023794 A5 JP WO2020023794A5 JP 2021527017 A JP2021527017 A JP 2021527017A JP 2021527017 A JP2021527017 A JP 2021527017A JP WO2020023794 A5 JPWO2020023794 A5 JP WO2020023794A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
hydrate
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021527017A
Other languages
English (en)
Other versions
JP2021532183A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043518 external-priority patent/WO2020023794A1/en
Publication of JP2021532183A publication Critical patent/JP2021532183A/ja
Publication of JPWO2020023794A5 publication Critical patent/JPWO2020023794A5/ja
Pending legal-status Critical Current

Links

Claims (15)

  1. 式(I)の構造を有する化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物であって、
    Figure 2020023794000001
    式中、
    Yはフェノール性TRPV1アゴニストであり、ここでフェノール性水酸基の水素原子は、
    Figure 2020023794000002
    との共有結合により置き換えられ、
    は水素またはC-Cアルキルであり、
    は、-(CHCHO)、-C(O)(CHO(CHCHO)、-C(O)O(CHCHO)、-C(O)N(R)(CHCHO)、-C(O)R、-C(O)OR、または-C(O)N(R)(R)であり、
    は水素またはC-Cアルキルであり、
    は水素またはC-Cアルキルであり、
    はC-C50アルキルであり、
    mは1~10であり、
    nは1~50であり、ならびに
    pは1~9である、化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物
  2. が、-(CHCHO)、-C(O)(CHO(CHCHO)、-C(O)O(CHCHO)、または-C(O)N(R)(CHCHO)である、請求項1に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物
  3. が-C(O)(CHO(CHCHO)である、請求項に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物
  4. mが1~5である、請求項に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物
  5. がC -C アルキルである、請求項4に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物。
  6. nが1~30である、請求項5に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物。
  7. nが2~12である、請求項6に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物。
  8. がC -C アルキルである、請求項7に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物。
  9. pが1である、請求項8に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物。
  10. Yが
    Figure 2020023794000003
    である、請求項9に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物。
  11. Yが
    Figure 2020023794000004
    である、請求項10に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物。
  12. 以下の構造:
    Figure 2020023794000005
    を有する、請求項11に記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物。
  13. 請求項1から12のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物と、薬学的に許容可能な希釈剤、賦形剤、または結合剤とを含む、医薬組成物。
  14. 被験体の疼痛を処置するための薬剤の製造における、請求項1から12のいずれか1つに記載の化合物、またはその薬学的に許容可能な塩、薬学的に許容可能な溶媒和物、あるいは水和物の使用。
  15. 前記疼痛は癌に関連する、請求項14に記載の使用。
JP2021527017A 2018-07-27 2019-07-25 フェノール性trpv1アゴニストのpeg化プロドラッグ Pending JP2021532183A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711361P 2018-07-27 2018-07-27
US62/711,361 2018-07-27
PCT/US2019/043518 WO2020023794A1 (en) 2018-07-27 2019-07-25 Pegylated prodrugs of phenolic trpv1 agonists

Publications (2)

Publication Number Publication Date
JP2021532183A JP2021532183A (ja) 2021-11-25
JPWO2020023794A5 true JPWO2020023794A5 (ja) 2022-07-29

Family

ID=69179028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527017A Pending JP2021532183A (ja) 2018-07-27 2019-07-25 フェノール性trpv1アゴニストのpeg化プロドラッグ

Country Status (10)

Country Link
US (5) US10717712B2 (ja)
EP (1) EP3830078A4 (ja)
JP (1) JP2021532183A (ja)
KR (1) KR20210073513A (ja)
CN (1) CN113166051A (ja)
AU (1) AU2019310118A1 (ja)
CA (1) CA3107433A1 (ja)
IL (1) IL280406A (ja)
TW (1) TW202019887A (ja)
WO (1) WO2020023794A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2017205534A1 (en) * 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
AU2019310118A1 (en) 2018-07-27 2021-03-11 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS624233A (ja) 1985-07-01 1987-01-10 Toyobo Co Ltd 組織性プラスミノ−ゲン活性化因子の製造法
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3684446D1 (de) 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5094782A (en) 1990-12-24 1992-03-10 National Science Council Of Republic Of China Synthesis of capsacin derivatives and their use as an analgesic drug and vessel dilation drug
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
CA2122479C (en) 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
CA2147283C (en) 1992-10-16 2007-01-16 Kouichi Nakamichi Method of manufacturing wax matrices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU720859B2 (en) 1997-03-13 2000-06-15 James N. Campbell Compositions containing capsaicin or capsaicin analogues and a local anesthetic
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2002193911A (ja) 2000-10-28 2002-07-10 Pfizer Prod Inc グルココルチコイドレセプターモジュレーター
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
ES2311756T3 (es) 2002-12-18 2009-02-16 Algorx Administracion de la capsiacina.
EP1605956B1 (en) 2002-12-18 2015-11-11 Centrexion Therapeutics Corporation Administration of capsaicinoids for the treatment of osteoarthritis
JP2005274260A (ja) 2004-03-24 2005-10-06 Fuji Photo Film Co Ltd 放射線撮像パネルを構成する光導電層の製造方法
CA2600696A1 (en) 2005-03-14 2006-09-21 Governors Of The University Of Alberta Synthetic anti-candida albicans oligosaccharide based vaccines
JP2008539253A (ja) * 2005-04-25 2008-11-13 ニューロジェシックス, インコーポレイテッド Trpv1アゴニスト化合物、ならびにtrpv1アゴニスト化合物を製造および使用するための方法
AU2007267510B2 (en) 2006-05-26 2013-01-31 Signature Therapeutics, Inc. Controlled release of phenolic opioids
US7943666B2 (en) 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
CA2689310A1 (en) 2007-05-30 2008-12-11 Brigham Young University Protein kinase-binding nucleosides and associated methods
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
AU2009305563C1 (en) 2008-10-17 2015-09-03 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
BR112012001164A2 (pt) 2009-07-17 2016-03-01 Shire Llc aminoácido de carbamato e pró-fármacos de peptídeo de opioides e usos dos mesmos
BR112012005124B1 (pt) * 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
BR112012026768A2 (pt) 2010-04-21 2015-09-29 Signature Therapeutics Inc composições compreendendo pró-farmacos de opioides cliváveis de modo enzimático e seus inibidores.
US20110262360A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
WO2011133346A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Peripheral opioid agonists and peripheral opioid antagonists
US20130089504A1 (en) 2010-04-21 2013-04-11 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug
US20110262359A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
WO2011133150A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
CA2814763C (en) 2011-01-11 2019-05-28 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012098557A1 (en) 2011-01-20 2012-07-26 Institute Of Life Sciences Pegylated gemcitabine derivative and process for preparing the same
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
US20120232066A1 (en) 2011-03-09 2012-09-13 Jenkins Thomas E Compositions for reducing risk of adverse events caused by drug-drug interactions
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
ITRM20130135A1 (it) 2013-03-06 2014-09-07 Michele Azzolini Nuovi derivati del resveratrolo.
US9636298B2 (en) * 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
KR101478520B1 (ko) 2014-01-24 2015-01-02 동신대학교산학협력단 피부 안전성이 향상된 캡사이신-펩타이드 및 이를 이용한 피부 외용제 조성물
FR3022784B1 (fr) 2014-06-26 2017-09-08 Ecole Normale Superieure Lyon Sondes moleculaires activables hydrosolubles, intermediaires pour leur synthese et procedes de detection associes
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US20170260131A1 (en) 2014-11-25 2017-09-14 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2017205534A1 (en) * 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
AU2019310118A1 (en) 2018-07-27 2021-03-11 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
WO2020023793A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists

Similar Documents

Publication Publication Date Title
JP2010533715A5 (ja)
JP2019031560A5 (ja)
JP2023126440A5 (ja)
JP2018138577A5 (ja)
JP2020507566A5 (ja)
JP2013502441A5 (ja)
JP2012529535A5 (ja)
JP2008520742A5 (ja)
JP2013528223A5 (ja)
JP2016503799A5 (ja)
JP2010509242A5 (ja)
JP2010523476A5 (ja)
JP2008525530A5 (ja)
JP2011504903A5 (ja)
JP2017538773A5 (ja)
JP2014015465A5 (ja)
JP2004507465A5 (ja)
JP2011509309A5 (ja)
JP2013512277A5 (ja)
JP2003520235A5 (ja)
JP2015503596A5 (ja)
JP2009514899A5 (ja)
JP2008510719A5 (ja)
JP2022071077A5 (ja)
JP2005511545A5 (ja)